Journey Colab
Judy is an MD with 20 years’ experience in the development of CNS-active drugs. She supports clients like Journey Colab with their clinical development and regulatory strategies.
This person is not in any offices
Journey Colab
Journey Colab is pursuing FDA approval of psychedelic therapies to heal individual mental health and strengthen communities. They plan to build a portfolio of plant-identical compounds. Their first compound in development is mescaline.